Ex?vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial.

已完结 20 由找论文发布于 2025/12/27 19:27:59

DOI:10.1182/blood.2024024968
作者：Sari Kyt?l?,?Ida V?nttinen,?Tanja Ruokoranta,?Anu Partanen,?Annasofia Holopainen,?Joseph Saad,?Milla E L Kuusisto,?Sirpa Koskela,?Riikka R?ty,?Maija It?l?-Remes,?Imre V?strik,?Minna Suvela,?Alun Parso
文献类型：期刊论文
补充材料：只需要正文

American Society of Hematology (ASH)

Abstract：Abstract: The B-cell lymphoma 2 inhibitor venetoclax has shown promise for treating acute myeloid leukemia (AML). However, identifying patients likely to respond remains a challenge, especia

应助信息

1小时前

追杀

2c7ba0cce31811f0aa6234735aa3bc31.pdf 已采纳

1小时前

Book学术机器人

2025/12/27 19:27:59 未找到该文献，机器人已退出，请等待人工下载

2025/12/27 19:27:59 Book学术AI机器人收到请求，开始寻找文献

2025/12/27 19:27:59 已向机器人发送请求

1小时前

找论文发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierSpatial-temporal monitoring of compound droughts over global land areas